Objective To determine the frequency and nature of copy number variants (CNVs) 
INTRODUCTION
Nuchal translucency (NT) is a collection of fluid at the back of the fetal neck; its thickness is measured on ultrasound examination between 10 and 13 + 6 weeks of gestation. An increased thickness of NT > 99 th centile, which corresponds approximately to a threshold of 3.5 mm, is associated with a risk of chromosomal abnormalities, genetic syndromes such as Noonan syndrome, Smith-Lemli-Opitz syndrome and congenital adrenal hyperplasia, and major structural birth defects [1] [2] [3] [4] [5] . Increased NT is also associated with an increased risk of miscarriage, intrauterine fetal death and developmental delay 4, 6 . Furthermore, the prevalence of several congenital malformations, for example heart defects, cleft lip and palate and diaphragmatic hernia, is higher than in the general population.
Recently, several studies have demonstrated the advantages of implementing chromosomal microarray analysis (CMA) in the prenatal setting. For example, in fetuses with isolated increased NT, a recent meta-analysis showed that CMA can detect about 4% of copy number variants (CNVs) not visible by karyotyping 7 . However, many of these studies included only a small number of cases, as well as fetuses with non-isolated increased NT. In addition, the classification of CNVs varies considerably between studies. The objective of our study was to determine the frequency and nature of CNVs identified by CMA in a large cohort of fetuses with strictly isolated increased NT ≥ 3.5 mm.
SUBJECTS AND METHODS
This was a retrospective, multicenter study including 11 French hospitals, whose databases were searched for cases assessed between April 2012 and December 2015. During this period, there were 720 fetuses with increased NT ≥ 3.5 mm measured between 10 and 13 + 6 weeks of gestation. Fetuses with NT unspecified, those with NT < 3.5 mm and those with any other finding on ultrasound were excluded.
Informed consent for genetic studies was obtained from all pregnant women. Depending on the gestational age, cytogenetic analyses were performed on samples from chorionic villi or amniotic fluid (AF). According to the particular center, the rapid technique used as the first step in searching for aneuploidies was either: MLPA (multiplex ligation-dependent probe amplification), BoBs (bacterial artificial chromosomes (BACs)-on-beads), QF-PCR (quantitative fluorescence-polymerase chain reaction) or direct chorionic villus sampling (CVS) preparation. When these cytogenetic analyses showed a normal result, CMA was performed. Fetuses with triploidy or sex chromosome aneuploidy diagnosed by one of the rapid techniques were excluded and did not undergo analysis by CMA. Clear AF samples were used for CMA directly, while blood-stained AF samples were cultured before performing CMA. One of three different types of microarray was used by each center: Agilent 60 K, Agilent 180 K or Agilent PreCytoNEM ® (Agilent Technologies, Santa Clara, CA, USA). The PreCytoNEM, a customized oligonucleotide microarray, was used by three centers to limit the identification of variants of uncertain significance (VOUS) and CNVs predisposing to neurodevelopmental disorders, as described previously 8 . For the purpose of this study, all CMA results were analyzed retrospectively by two medical cytogeneticists. The size, genomic position and gene content of any CNVs were evaluated for clinical significance. The published literature and public databases, such as DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources, https://decipher.sanger.ac.uk), the Database of Genomic Variants (http://dgv.tcag.ca/dgv/ app/home) and the International Standards for Cytogenomic Arrays Consortium (https://www.iscaconsortium .org), were also consulted to facilitate the interpretation of any CNVs detected. Aberrant chromosomal segments were assessed according to the human reference genome, genome build GRCh37/hg19. When a CNV was detected, FISH analysis had been performed on the fetus to confirm the findings and on the parents to determine the mode of inheritance. In cases of small duplications, family trio analyses (proband and parents) by microarray or qPCR were also carried out. When conventional cytogenetic analysis had not been performed in addition to CMA, we considered CNVs with a size ≥ 10 Mb to be visible by karyotyping, while CNVs < 10 Mb were considered to be not visible by karyotyping and were classified as cryptic. For cases with confined placental mosaicism suspected on direct CVS, a fetal karyotype and/or CMA from cultured CVS and amniotic fluid had also been performed.
We classified CNVs into five groups: clinically relevant CNVs or pathogenic CNVs; normal or benign CNVs; CNVs predisposing to neurodevelopmental disorders (i.e. CNVs with incomplete penetrance and variable expressivity); VOUS; and CNVs not related to the phenotype (i.e. an incidental finding).
We collected information regarding the age of the woman, gestational age at testing, NT thickness, techniques used, cytogenetic results and pregnancy outcome. Each center provided their data in the form of a spreadsheet. Figure 1 summarizes the fetuses included in our cohort. Of the 720 pregnancies with increased fetal NT at 10 to 13 + 6 weeks of gestation that were assessed during the study period, the invasive procedure was carried out by CVS or amniocentesis in 564 (78%) and 156 (22%) pregnancies, respectively. Rapid aneuploidy test (FISH, MLPA, BoBs, QF-PCR, direct CVS) showed 121 (16.8%) cases to have an aneuploidy involving chromosome 13, 18, 21 or X. The remaining 599 cases underwent CMA. Their median maternal age was 31 (range, 14-45) years, median gestational age at invasive testing was 13 (range, 11-28) weeks and median NT thickness was 4.3 (range, 3.5-15.0) mm. A CNV was detected in 53 of the 599 (8.8%) euploid fetuses: 16 (2.7%) were considered pathogenic (Table 1) , of which 11 (1.8%) were cryptic, eight (1.3%) were classified as VOUS (Table 2) , seven (1.2%) corresponded to genomic disorders with incomplete penetrance and variable expressivity (Table 3 ) and one (0.2%) CNV was unrelated to the reason for referral diagnosis (i.e. an incidental finding; Table 4 ). The remaining 21 were benign CNVs, i.e. without clinical consequence.
RESULTS
Six of the pathogenic CNVs corresponded to known syndromes: a 3p-syndrome, a 5q14.3 deletion syndrome, a 5q35.2q35.3 deletion associated with SOTOS1 syndrome, a 20p12.3p12.2 deletion associated with Alagille syndrome 1, a 22q11.2 duplication syndrome and a 22q13 duplication syndrome.
The distribution of the different types of CNV according to NT thickness is presented in Table 5 . The NT thickness thresholds used correspond to those used by Souka et al. 4 . We found four (1.2%) cryptic pathogenic CNVs among the 343 fetuses with NT between 3.5 and 4.4 mm, three (2.4%) among the 124 fetuses with NT between 4.5 and 5.4 mm and four (5.5%) among the 73 fetuses with NT between 5.5 and 6.4 mm. We did not identify any cryptic pathogenic CNVs among the 59 fetuses with NT ≥ 6.5 mm.
Termination of pregnancy was chosen by 12 of the 16 (75%) cases with a finding of pathogenic CNV (Table 1) , three of the eight (38%) cases with VOUS and three of the seven (43%) cases of CNV with incomplete penetrance and/or variable expressivity (Tables 2 and 3) .
DISCUSSION
In the last few years, several studies have demonstrated the advantages of implementing microarray technology in the prenatal setting. Pathogenic submicroscopic CNVs are detected in about 6% of fetuses with ultrasound anomalies, with cardiac, skeletal, urogenital, renal and central nervous system abnormalities being the most likely associated ultrasound anomalies 9, 10 . Increased fetal NT also corresponds to a common phenotypic expression of genomic imbalances such as aneuploidies (trisomy 21, 18 and 13, triploidies and monosomy X), as well as segmental chromosomal anomalies 2 . A recent meta-analysis of 17 studies by Grande et al. 7 indicated that the use of microarrays in fetuses with increased NT and normal karyotype yields additional disease-causing submicroscopic CNVs in 4% (95% CI, 2-7%) of cases.
In our retrospective study involving 11 centers, 599 fetuses were investigated by CMA after excluding classical chromosomal anomalies by a rapid aneuploidy test. Our findings of clinically relevant CNVs identified a further 16 cases, increasing by 2.7% the diagnostic yield in the study cohort of 720 fetuses with isolated increased NT. Eleven (69%, and 1.8% of the cohort) of those identified would not have been visible by karyotyping. This detection rate is lower than the 4% reported by Grande et al. 7 . However, de Wit et al. 10 reported that the detection rate of cryptic CNVs can reach 7% when testing those with increased NT in association with at least one other ultrasound finding. In our study, only fetuses with apparently isolated increased NT were included, thereby limiting the likelihood of detecting an anomaly.
Interestingly, we found only one fetus with a 22q11.21 duplication syndrome, yet recurrent rearrangements of the 22q11.2 region are the most frequent CNVs reported. In a review of the literature, we searched for studies in which fetuses with isolated NT ≥ 3.5 mm underwent CMA and which provided a detailed list of CNVs identified. This review yielded a total of 17 studies, including 1076 fetuses [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] (Table S1 ). Among them, 36 CNVs classified as pathogenic were identified, including seven CNVs (19%) at the 22q11.2 locus (five duplications and two deletions). 22q11.2 genomic imbalances are usually associated with conotruncal cardiac defects, as well as other ultrasound findings, such as polyhydramnios, cleft palate and kidney malformations. Thus, our recruitment of fetuses with a strictly isolated increased NT may have excluded those harboring a 22q11.21 CNV.
It is worth noting that most studies group CNVs associated with a highly variable phenotype and incomplete penetrance along with clinically relevant CNVs. This could also account for the lower detection rate of pathogenic CNVs in our study. Although such CNVs can be associated with neurodevelopmental disorders including autism spectrum disorders, schizophrenia, attention deficit with hyperactivity disorder and intellectual disability, they can also be found in asymptomatic carriers. Since, in the prenatal setting, we cannot determine the neurodevelopmental phenotype, these CNVs raise significant challenges for genetic counseling, and they should not be interpreted in the same manner as is a pathogenic CNV. It is for this reason that some laboratories do not report them in the prenatal setting. In our study, three centers, including 190 of the 599 (32%) samples, performed CMA with the PreCytoNEM chip. This system was designed to lack oligonucleotides, and would therefore not have detected any CNVs, in regions responsible for susceptibility to neurodevelopmental disorders (such as 1q21.1 (MIM #612474/612475), 15q11.2 MIM (#615656), 15q13.3 (MIM #612001) and 16p11.2 (MIM #611913/614671)). Hence, the detection rate (7/599, 1.2%) of these CNVs was likely underestimated in our study. We detected five cases with a CNV in the 15q11.2 and 1q21.1 regions: four 15q11.2 deletions (one of which was larger because it also encompassed the proximal polymorphic 15q11.1 region) and one 1q21.1 deletion. These recurrent CNVs, which can be associated with neurodevelopmental disorders, are also significantly associated with sporadic, non-syndromic congenital heart defects (CHD) [28] [29] [30] . The 15q11.2 region between BP1 and BP2 segmental duplications encompasses four genes (NIPA1, NIPA2, TUBGCP5 and CYFIP1) which are highly conserved and expressed biallelically. Two of them, TUBGCP5 and NIPA1, are reportedly expressed in the fetal heart (Bgee database 31 https://bgee.org), which increases the probability of their being causative genes for a CHD. Regarding the 1q21.1 segment, previous studies in mice and humans suggest strongly that the GJA5 gene, which encodes connexin-40, is the critical gene for the CHD phenotype 29, 32 . Given the known relationship between increased NT and CHD 33, 34 , the detection of deletions at 15q11.2 and 1q21.1 loci is worth investigating further. Unfortunately, our five fetuses harboring these CNVs did not have follow-up information available.
The prevalence of fetal chromosomal anomalies and adverse pregnancy outcome increase with increasing thickness of the NT 4 . Our findings mostly support that the detection rate of cryptic pathogenic CNVs increased with increasing NT thickness, our detection rate being 5.5% in fetuses with NT between 5.5 and 6.4 mm, 2.4% in those with NT between 4.5 and 5.4 mm and 1.2% in those with NT between 3.5 and 4.4 mm. In fetuses with NT ≥ 6.5 mm, no cryptic pathogenic CNV was identified, possibly due to the small number of fetuses in this group (n = 59).
In conclusion, our study suggests that performing CMA in fetuses presenting with isolated increased NT at the first-trimester scan will provide a significant benefit, since approximately 2% of cases have a cryptic pathogenic CNV. Furthermore, we detected genomic imbalances (i.e. 1q21.1 and 15q11.2) that are associated with sporadic non-syndromic CHD. Further investigations are necessary to determine the relationship between increased NT and these CNVs.
